Compare Novo Nordisk A/S (NVO) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vale SA — how do they compare? Novo Nordisk A/S trades at $49.36 (market cap $220.53B), while Vale SA trades at $14.13 (market cap $59.07B). The key difference: Novo Nordisk A/S is far larger — about 3.7× Vale SA's market cap, and Vale SA pays the higher dividend (8.93%). Which is the better fit depends on your goals.
| NVO | VALE | |
|---|---|---|
Market Cap | $220.53B | $59.07B |
Sector | Health | Basic Materials |
52-Week High | $71.70 | $17.82 |
52-Week Low | $35.29 | $9.53 |
Enterprise Value | $239.49B | $75.99B |
Dividend Yield | 3.63% | 8.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
VALE trades at $14.25, up 0.42% today but down 11% over the past month. Technical indicators show a bearish trend with moving averages signaling sell pressure. Fundamentally, revenue declined to $38.4B in 2025 with net income falling to $2.35B, though cash flow improved to $2.42B. Recent news highlights board governance disputes and a $2.6B decarbonization investment announced in June 2026.
The outlook remains cautious with mixed analyst ratings (40.5% buy, 48.7% hold) and a $17.13 consensus target. Risks include volatile iron ore prices and execution challenges, but stable cash flow and low debt provide some resilience. Upside depends on commodity demand recovery and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
